Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
arcticnovartis
- Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM(INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy setting for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
- New analysis of key subgroups of clinical interest from NATALEE reinforces the potential of Kisqali®(ribociclib) plus endocrine therapy (ET) to consistently reduce the risk of cancer recurrence across a broad popu